PPD, Inc. (PPD) |
| 47.28 0 (0%) 04-24 15:47 |
| Open: | 47.32 |
| High: | 47.4 |
| Low: | 47.24 |
| Volume: | 1,868,187 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 145.37 |
| Resistance 1: | 137.99 |
| Pivot price: | 138.29 |
| Support 1: | 126.05 |
| Support 2: | 104.87 |
| 52w High: | 47.41 |
| 52w Low: | 31.54 |
PPD, Inc. delivers a full spectrum of drug development services internationally, primarily catering to the biopharmaceutical industry. The company structures its operations across two core divisions: Clinical Development Services and Laboratory Services. Under its Clinical Development arm, PPD provides a diverse range of support, including initial product strategy and advisory services, early-stage development, end-to-end management of clinical trials from Phase II through Phase IV, techniques for accelerated patient recruitment, assistance with pre- and post-market approval processes, and various medical communication solutions. Furthermore, its Laboratory Services segment encompasses specialized capabilities such as bioanalytical analysis, biomarker identification, vaccine science expertise, adherence to Good Manufacturing Practice (GMP) guidelines, and centralized laboratory testing. The firm's extensive client base reaches beyond pharmaceutical and biotechnology companies to include manufacturers of medical devices, governmental organizations, and other participants throughout the industry. PPD, Inc. was established in 1985 and maintains its corporate headquarters in Wilmington, North Carolina.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Wed, 28 Feb 2024
Medidata and Thermo Fisher Scientific’s PPD Clinical Research Business Collaborate to Accelerate Clinical Trials Innovation - Dassault Systèmes
Sun, 09 Jul 2023
PPD - Carlyle
Thu, 09 Dec 2021
Thermo Fisher Scientific Completes Acquisition of PPD, Inc. - BioPharma APAC
Thu, 09 Dec 2021
Thermo Fisher acquires clinical research services provider PPD for $17.4bn - Pharmaceutical Technology
Wed, 08 Dec 2021
Thermo Fisher Scientific Completes PPD Acquisition - Contract Pharma
Wed, 08 Dec 2021
Thermo Fisher Completes Purchase Of PPD - WilmingtonBiz
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |